

Financial Tear Sheet

Company Profile

Merus discovers and develops differentiated therapeutics aimed at substantially prolonging the lives of cancer patients. It is our strategy to use the power of bispecific antibody engineering and advanced screening technologies to develop biopharmaceuticals that engage the power of the immune system to kill tumor cells.

Share Performance

MRUS (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$17.91
Change (%)	▲ 0.09 (0.51%)
Volume	31,716
52 Week Low	\$13.23
Market Cap	\$347,988,578
Rolling EPS	-5.00
PE Ratio	0
Shares Outstanding	19,429,848
Data as of 05/18/18 3:59 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

News & Events

Date	Title
05/15/18	Merus Announces Unique Mechanism of Action of MCLA-128 That Potently Blocks HER3 Signaling Published in Cancer

There are currently no events scheduled.

Cell	
04/26/18	Merus Announces Recent Corporate Developments and Financial Results for the Fourth Quarter and Full Year 2017
04/19/18	Merus to Report Full Year 2017 Financial Results and Corporate Developments on April 26, 2018

SEC Filings

Filing Date	Form
05/15/18	F-3
04/30/18	20-F
04/27/18	6-K
03/16/18	6-K

Supervisory Board

Ton Logtenberg, Ph.D	CEO, Executive Director
Mark Iwicki	Chairman, Non-Executive Director
Wolfgang Berthold, Ph.D.	Non-Executive Director
Anand Mehra, M.D.	Non-Executive Director
Lionel Carnot	Non-Executive Director
John de Koning, Ph.D.	Non-Executive Director
Gregory Perry	Non-Executive

Primary IR Contact

Kimberly Minarovich
 Argot Partners
 Phone: 1 212-600-1902
 E-mail: kimberly@argotpartners.com

Management Board

Ton Logtenberg, Ph.D	CEO
Shelley Margetson	CFO

Director